Manning & Napier Advisors LLC increased its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 1.8% during the third quarter, Holdings Channel reports. The firm owned 142,410 shares of the company’s stock after buying an additional 2,490 shares during the period. Manning & Napier Advisors LLC’s holdings in BioMarin Pharmaceutical were worth $13,174,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently made changes to their positions in the stock. Hartford Investment Management Co. increased its position in shares of BioMarin Pharmaceutical by 2.5% in the second quarter. Hartford Investment Management Co. now owns 2,906 shares of the company’s stock valued at $226,000 after buying an additional 70 shares during the period. LS Investment Advisors LLC increased its stake in shares of BioMarin Pharmaceutical by 13.5% in the second quarter. LS Investment Advisors LLC now owns 1,946 shares of the company’s stock valued at $151,000 after buying an additional 231 shares during the last quarter. Parametrica Management Ltd increased its stake in shares of BioMarin Pharmaceutical by 149.4% in the second quarter. Parametrica Management Ltd now owns 6,507 shares of the company’s stock valued at $506,000 after buying an additional 3,898 shares during the last quarter. Meeder Asset Management Inc. bought a new stake in shares of BioMarin Pharmaceutical during the second quarter valued at about $140,000. Finally, Shell Asset Management Co. increased its stake in shares of BioMarin Pharmaceutical by 23.3% in the second quarter. Shell Asset Management Co. now owns 27,415 shares of the company’s stock valued at $2,133,000 after buying an additional 5,179 shares during the last quarter. Institutional investors own 97.48% of the company’s stock.

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) opened at 86.15 on Friday. The company has a 50-day moving average price of $85.10 and a 200-day moving average price of $89.60. The firm’s market capitalization is $14.82 billion. BioMarin Pharmaceutical Inc. has a 12 month low of $62.12 and a 12 month high of $102.49.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its earnings results on Thursday, October 27th. The company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.13. BioMarin Pharmaceutical had a negative return on equity of 8.54% and a negative net margin of 46.22%. The firm had revenue of $279.90 million for the quarter, compared to the consensus estimate of $289.70 million. During the same quarter in the prior year, the business earned ($0.60) EPS. The business’s revenue for the quarter was up 34.0% on a year-over-year basis. Equities analysts forecast that BioMarin Pharmaceutical Inc. will post ($3.73) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was first published by Daily Political and is the sole property of of Daily Political. If you are reading this story on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this story can be read at http://www.dailypolitical.com/2017/01/13/manning-napier-advisors-llc-has-13174000-stake-in-biomarin-pharmaceutical-inc-bmrn.html.

Several equities research analysts have recently issued reports on BMRN shares. Zacks Investment Research upgraded shares of BioMarin Pharmaceutical from a “hold” rating to a “buy” rating and set a $106.00 price objective on the stock in a research note on Tuesday, October 4th. Robert W. Baird set a $115.00 price objective on shares of BioMarin Pharmaceutical and gave the stock a “buy” rating in a research note on Saturday, October 15th. J P Morgan Chase & Co restated a “buy” rating and issued a $127.00 price objective on shares of BioMarin Pharmaceutical in a research note on Monday, October 31st. RBC Capital Markets set a $125.00 price objective on shares of BioMarin Pharmaceutical and gave the stock a “buy” rating in a research note on Sunday, October 30th. Finally, Vetr downgraded shares of BioMarin Pharmaceutical from a “strong-buy” rating to a “buy” rating and set a $90.22 price objective on the stock. in a research note on Monday, November 7th. Five analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $113.57.

In related news, CEO Jean Jacques Bienaime sold 8,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 11th. The stock was sold at an average price of $90.58, for a total value of $724,640.00. Following the sale, the chief executive officer now owns 174,682 shares in the company, valued at approximately $15,822,695.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Daniel K. Spiegelman sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, January 9th. The stock was sold at an average price of $90.00, for a total value of $450,000.00. Following the completion of the sale, the chief financial officer now owns 18,100 shares in the company, valued at approximately $1,629,000. The disclosure for this sale can be found here. Company insiders own 2.50% of the company’s stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc (BioMarin) develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company’s product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. Its approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate).

5 Day Chart for NASDAQ:BMRN

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN).

Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.